• LAVA Therapeutics NV LVTX.OQ reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of three analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -36 cents to -30 cents per share.

• Reported revenue was zero​; analysts expected zero.

• LAVA Therapeutics NV's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $12.3 million.

• LAVA Therapeutics NV shares had risen by 15.1% this quarter and gained 20.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for LAVA Therapeutics NV is $6.00

This summary was machine generated from LSEG data December 10 at 02:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)